Source: New England Journal of Medicine, first published online September 8, 2026; October 29 journal issue; OBERON and TITANIA phase 3 randomized, double-blind trials; primary article · DOI 10.1056/NEJMoa2606998. Evidence: high-quality paired randomized evidence. Clinical state: specialist appraisal now; investigational drug and indication require contemporaneous regulatory review.
An exacerbation of chronic obstructive pulmonary disease is not an abstract disease marker. It may mean another course of treatment, an ambulance ride, or the loss of confidence to leave home. Both OBERON and TITANIA tested whether inhibiting interleukin-33 could prevent these episodes in people who continued standard inhaled maintenance treatment despite previous exacerbations. Participants received 300 mg subcutaneous tozorakimab or placebo every four weeks for 52 weeks.
In former smokers, annualized moderate or severe exacerbations fell from 1.90 to 1.34 in OBERON (rate ratio 0.71, 95% CI 0.57–0.88) and from 2.07 to 1.37 in TITANIA (rate ratio 0.66, 95% CI 0.55–0.80). Similar findings appeared in the full current- and former-smoker populations. The overall-analysis groups reported about 0.59 fewer exacerbations per patient-year in each trial, an understandable gain even though rates are population averages rather than promised individual events. Reported overall adverse-event percentages were 70.4% versus 77.2% and 80.1% versus 79.8%, respectively.
What this changes: There is convincing randomized evidence for fewer exacerbations in the enrolled populations, with replication across two trials. Long-term survival, comparative effectiveness against other biologics, real-world access, and cost-effectiveness remain separate questions. Do not extrapolate efficacy to all COPD phenotypes or assume it is already routinely available.
Keep reading on this subject
Inflammation · Care & independence